NZ581836A - A drug delivery system for the prevention of cerebral vasospasm - Google Patents

A drug delivery system for the prevention of cerebral vasospasm

Info

Publication number
NZ581836A
NZ581836A NZ581836A NZ58183608A NZ581836A NZ 581836 A NZ581836 A NZ 581836A NZ 581836 A NZ581836 A NZ 581836A NZ 58183608 A NZ58183608 A NZ 58183608A NZ 581836 A NZ581836 A NZ 581836A
Authority
NZ
New Zealand
Prior art keywords
calcium channel
vasospasm
use according
cerebral
type voltage
Prior art date
Application number
NZ581836A
Other languages
English (en)
Inventor
Brian Leuthner
R Loch Macdonald
Original Assignee
R Loch Macdonald
Brian Leuthner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R Loch Macdonald, Brian Leuthner filed Critical R Loch Macdonald
Priority to NZ599430A priority Critical patent/NZ599430A/en
Publication of NZ581836A publication Critical patent/NZ581836A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ581836A 2007-06-11 2008-06-11 A drug delivery system for the prevention of cerebral vasospasm NZ581836A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ599430A NZ599430A (en) 2007-06-11 2008-06-11 A drug delivery system for the prevention of cerebral vasospasm

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94312407P 2007-06-11 2007-06-11
US97690207P 2007-10-29 2007-10-29
PCT/US2008/066576 WO2008154585A1 (en) 2007-06-11 2008-06-11 A drug delivery system for the prevention of cerebral vasospasm

Publications (1)

Publication Number Publication Date
NZ581836A true NZ581836A (en) 2012-07-27

Family

ID=40096090

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ581836A NZ581836A (en) 2007-06-11 2008-06-11 A drug delivery system for the prevention of cerebral vasospasm
NZ599430A NZ599430A (en) 2007-06-11 2008-06-11 A drug delivery system for the prevention of cerebral vasospasm

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ599430A NZ599430A (en) 2007-06-11 2008-06-11 A drug delivery system for the prevention of cerebral vasospasm

Country Status (10)

Country Link
US (2) US8303974B2 (cg-RX-API-DMAC7.html)
EP (1) EP2164497B1 (cg-RX-API-DMAC7.html)
JP (1) JP5576790B2 (cg-RX-API-DMAC7.html)
KR (3) KR101554250B1 (cg-RX-API-DMAC7.html)
CN (3) CN101873858B (cg-RX-API-DMAC7.html)
AU (1) AU2008261668C1 (cg-RX-API-DMAC7.html)
CA (1) CA2690600C (cg-RX-API-DMAC7.html)
IL (1) IL202647A (cg-RX-API-DMAC7.html)
NZ (2) NZ581836A (cg-RX-API-DMAC7.html)
WO (1) WO2008154585A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101554250B1 (ko) * 2007-06-11 2015-09-18 알. 로치 맥도날드 뇌혈관 연축의 예방을 위한 약물 전달 시스템
US10092524B2 (en) * 2008-06-11 2018-10-09 Edge Therapeutics, Inc. Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage
EP2308478A1 (en) 2009-10-06 2011-04-13 Abbott GmbH & Co. KG Delivery system for sustained release of a calcium-channel blocking agent
CN102834104A (zh) * 2010-02-22 2012-12-19 优势医疗公司 治疗脑的出血性病状的方法和组合物
EP2627173B2 (en) 2010-10-12 2018-07-04 Chiesi Farmaceutici S.p.A. Clevidipine emulsion formulations containing antimicrobial agents
US8658676B2 (en) * 2010-10-12 2014-02-25 The Medicines Company Clevidipine emulsion formulations containing antimicrobial agents
CN107115270A (zh) * 2011-02-11 2017-09-01 优势医疗公司 用于改善患有蛛网膜下腔出血的人的预后的组合物和方法
EP2694133B1 (en) * 2011-04-05 2018-05-23 Edge Therapeutics, Inc. Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow
CN102416013A (zh) * 2011-12-30 2012-04-18 湖南九典制药有限公司 西尼地平的新用途
US9399019B2 (en) * 2012-05-09 2016-07-26 Evonik Corporation Polymorph compositions, methods of making, and uses thereof
US9655999B2 (en) 2013-03-12 2017-05-23 Carnegie Mellon University Coated vaso-occlusive device for treatment of aneurysms
CN103211812A (zh) * 2013-04-02 2013-07-24 苏州大学附属第一医院 Skf96365在治疗蛛网膜下腔出血后发生的脑血管痉挛的应用
US10403395B2 (en) * 2013-10-14 2019-09-03 SecondOpinionExpert, Inc. Method and apparatus for generating objective medical second opinion
CN107427666B (zh) * 2015-01-30 2022-11-04 加利福尼亚大学校董 脊髓软膜下基因递送系统
GB2556500A (en) * 2015-05-29 2018-05-30 Edge Therapeutics Inc Compositions and methods for reducing visual loss
WO2017024032A2 (en) * 2015-08-03 2017-02-09 Enb Therapeutics, Llc Compositions and methods for treating cancers associated with etbr activation
IL271908B2 (en) 2017-07-11 2024-02-01 Sustained Nano Systems Llc Hypercompressed pharmaceutical formulations
US10435434B2 (en) 2018-01-12 2019-10-08 Enb Therapeutics, Inc. Deuterated compounds, compositions, and methods for treating cancers associated with ETBR activation
US20200163947A1 (en) * 2018-11-02 2020-05-28 Nortic Holdings Inc. Methods of treatment using nimodipine parenteral formulations
US20200315547A1 (en) * 2019-04-02 2020-10-08 Tencent America LLC Vertebral artery dissection risk evaluation method, computer device, and storage medium
US11103142B2 (en) * 2019-04-02 2021-08-31 Tencent America LLC System and method for predicting vertebral artery dissection
JP7716076B2 (ja) * 2021-02-04 2025-07-31 学校法人産業医科大学 血管内穿孔によるくも膜下出血モデルの血腫を可視化する方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650489A (en) * 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
JPH09507487A (ja) 1994-01-05 1997-07-29 アーキュール，インコーポレーテッド 選ばれた性質を有するアミンイミドおよびオキサゾロンをベースとした分子の系統的モジュール製造
US5712171A (en) * 1995-01-20 1998-01-27 Arqule, Inc. Method of generating a plurality of chemical compounds in a spatially arranged array
JP2909418B2 (ja) * 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
ATE314843T1 (de) 1996-03-12 2006-02-15 Pg Txl Co Lp Wasserlösliche paclitaxel-prodrogen
CA2296056A1 (en) * 1997-07-10 1999-01-21 Keith Baker Methods for universally distributing therapeutic agents to the brain
US6284283B1 (en) * 1999-10-21 2001-09-04 Alkermes Controlled Therapeutics, Inc. Method of producing sub-micron particles of biologically active agents and uses thereof
JP2002003406A (ja) * 2000-06-21 2002-01-09 Sankyo Co Ltd 脳血管攣縮予防製剤
US20030032676A1 (en) * 2001-08-09 2003-02-13 Kimelberg Harold K. Drugs for treatment of cerebral injury and methods of use thereof
US20040224030A1 (en) * 2003-05-06 2004-11-11 Shastri Venkatram R. Microsphere delivery systems
EP2444069B1 (en) * 2003-07-23 2019-06-05 Evonik Corporation Controlled release compositions
CN1480128A (zh) * 2003-08-06 2004-03-10 北京扬新科技有限公司 一种透明、隐形的外用药物制剂
CN1856296A (zh) * 2003-09-30 2006-11-01 阿库斯菲尔公司 可注射的、口服、或局部用缓释药物制剂
US20060205733A1 (en) 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
US7829527B2 (en) * 2005-02-02 2010-11-09 University Of Vermont And State Agricultural College Emergence of a R-type Ca2+ channel (Cav 2.3) contributes to cerebral artery constriction following subarachnoid hemorrhage
US20060217340A1 (en) * 2005-03-23 2006-09-28 University Of Vermont And State Agricultural College Methods and products for treating hypertension by modulation of TRPC3 channel activity
KR101554250B1 (ko) * 2007-06-11 2015-09-18 알. 로치 맥도날드 뇌혈관 연축의 예방을 위한 약물 전달 시스템

Also Published As

Publication number Publication date
KR101554250B1 (ko) 2015-09-18
KR20100055385A (ko) 2010-05-26
NZ599430A (en) 2014-03-28
AU2008261668B2 (en) 2013-08-29
EP2164497B1 (en) 2018-08-15
KR20150015514A (ko) 2015-02-10
EP2164497A4 (en) 2013-05-29
IL202647A (en) 2015-02-26
WO2008154585A1 (en) 2008-12-18
CN105963242A (zh) 2016-09-28
IL202647A0 (en) 2010-06-30
AU2008261668C1 (en) 2014-01-16
CN101873858B (zh) 2016-05-25
JP5576790B2 (ja) 2014-08-20
JP2010529205A (ja) 2010-08-26
EP2164497A1 (en) 2010-03-24
US20130022660A1 (en) 2013-01-24
US20080305147A1 (en) 2008-12-11
KR101607244B1 (ko) 2016-03-30
KR20150061031A (ko) 2015-06-03
KR101554258B1 (ko) 2015-09-18
CN101873858A (zh) 2010-10-27
AU2008261668A1 (en) 2008-12-18
CA2690600C (en) 2016-10-11
CN105055300A (zh) 2015-11-18
US8303974B2 (en) 2012-11-06
CA2690600A1 (en) 2008-12-18

Similar Documents

Publication Publication Date Title
US8303974B2 (en) Drug delivery system for the prevention of cerebral vasospasm
AU2012240131B2 (en) Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow
AU2012214137B2 (en) Compositions and methods for improving prognosis of a human with subarachnoid hemorrhage
AU2016201681B2 (en) A drug delivery system for the prevention of cerebral vasospasm
AU2013203192B2 (en) A drug delivery system for the prevention of cerebral vasospasm
CA2826890A1 (en) Compositions and methods for improving prognosis of a human with subarachnoid hemorrhage
HK1229243A1 (en) A drug delivery system for the prevention of cerebral vasospasm
NZ613970B2 (en) Compositions and methods for improving prognosis of a human with subarachnoid hemorrhage
NZ727856B2 (en) Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow
NZ714032B2 (en) Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 11 JUN 2015 BY CPA GLOBAL

Effective date: 20130117

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 JUN 2016 BY CPA GLOBAL

Effective date: 20150502

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 JUN 2017 BY CPA GLOBAL

Effective date: 20160429

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 JUN 2018 BY CPA GLOBAL

Effective date: 20170505

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 JUN 2019 BY COMPUTER PACKAGES INC

Effective date: 20180518

LAPS Patent lapsed